NCT06912087 - Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

June 5, 2027

Study Completion Date

June 5, 2027

Conditions

Head and Neck NeoplasmsCarcinoma, Squamous CellNeoplasm Recurrence, LocalNeoplasm MetastasisRecurrent Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma

Interventions

DRUG

Zanzalintinib

Experimental receptor tyrosine kinases (RTKs)

DRUG

Cetuximab

Food and Drug Administration (FDA) approved monoclonal antibody directed against the epidermal growth factor (EGFR).

DRUG

Pembrolizumab

FDA approved monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1)

Trial Locations (1)

60637

University of Chicago Medicine Comprehensive Cancer Center, Chicago